![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP...
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.07 | -0.625 | 11.2 | 11.79 | 11.1 | 239 | 11.4290142 | DR |
4 | 1.38 | 14.1538461538 | 9.75 | 11.79 | 9.41 | 161 | 11.09974835 | DR |
12 | 1.13 | 11.3 | 10 | 11.79 | 8.75 | 162 | 10.19814516 | DR |
26 | -1.06 | -8.69565217391 | 12.19 | 12.49 | 8.75 | 1051 | 10.90646787 | DR |
52 | -4.49 | -28.7451984635 | 15.62 | 16.44 | 8.75 | 759 | 10.9157266 | DR |
156 | -40.52 | -78.4511132623 | 51.65 | 55.76 | 8.75 | 1646 | 42.93238717 | DR |
260 | -43.37 | -79.5779816514 | 54.5 | 60.55 | 8.75 | 2434 | 48.04657703 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions